Shares of MAXIMUS, Inc. (NYSE:MMS) have earned a consensus rating of “Hold” from the eight brokerages that are currently covering the stock, Marketbeat.com reports. One investment analyst has rated the stock with a sell recommendation, five have given a hold recommendation and one has issued a buy recommendation on the company. The average 1-year target price among brokerages that have issued ratings on the stock in the last year is $67.25.
MMS has been the subject of several recent research reports. Canaccord Genuity decreased their target price on shares of MAXIMUS from $62.00 to $61.00 and set a “hold” rating for the company in a research report on Friday, November 10th. Zacks Investment Research raised shares of MAXIMUS from a “hold” rating to a “buy” rating and set a $71.00 target price for the company in a research report on Tuesday, February 13th. Finally, Maxim Group reissued a “hold” rating and issued a $69.00 target price (up from $66.00) on shares of MAXIMUS in a research report on Thursday, February 8th.
MAXIMUS (NYSE MMS) traded up $0.23 during mid-day trading on Wednesday, reaching $67.88. 276,543 shares of the company’s stock traded hands, compared to its average volume of 520,931. The company has a debt-to-equity ratio of 0.01, a current ratio of 2.57 and a quick ratio of 2.57. The company has a market capitalization of $4,358.88, a P/E ratio of 20.17, a price-to-earnings-growth ratio of 2.22 and a beta of 1.18. MAXIMUS has a 12 month low of $57.12 and a 12 month high of $72.71.
MAXIMUS (NYSE:MMS) last posted its earnings results on Thursday, February 8th. The health services provider reported $0.78 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $0.77 by $0.01. The company had revenue of $623.10 million during the quarter, compared to the consensus estimate of $624.36 million. MAXIMUS had a net margin of 8.99% and a return on equity of 22.93%. The company’s revenue for the quarter was up 2.6% compared to the same quarter last year. During the same period in the previous year, the firm posted $0.71 earnings per share. sell-side analysts expect that MAXIMUS will post 3.44 earnings per share for the current fiscal year.
The company also recently disclosed a quarterly dividend, which was paid on Wednesday, February 28th. Stockholders of record on Thursday, February 15th were paid a $0.045 dividend. This represents a $0.18 dividend on an annualized basis and a dividend yield of 0.27%. The ex-dividend date was Wednesday, February 14th. MAXIMUS’s payout ratio is 5.36%.
In other news, Director Russell A. Beliveau sold 1,000 shares of the business’s stock in a transaction on Tuesday, January 2nd. The shares were sold at an average price of $71.73, for a total value of $71,730.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CEO Richard A. Montoni sold 30,000 shares of the business’s stock in a transaction on Thursday, December 7th. The stock was sold at an average price of $69.25, for a total transaction of $2,077,500.00. The disclosure for this sale can be found here. Insiders sold 77,300 shares of company stock valued at $5,286,730 over the last 90 days. 2.48% of the stock is owned by corporate insiders.
Several institutional investors have recently modified their holdings of MMS. Mondrian Investment Partners LTD acquired a new stake in shares of MAXIMUS in the fourth quarter worth $51,945,000. Arrowstreet Capital Limited Partnership lifted its stake in shares of MAXIMUS by 1,629.4% in the fourth quarter. Arrowstreet Capital Limited Partnership now owns 389,120 shares of the health services provider’s stock worth $27,853,000 after buying an additional 366,620 shares during the last quarter. APG Asset Management N.V. lifted its stake in shares of MAXIMUS by 316.2% in the fourth quarter. APG Asset Management N.V. now owns 380,800 shares of the health services provider’s stock worth $22,700,000 after buying an additional 289,300 shares during the last quarter. Schwab Charles Investment Management Inc. lifted its stake in shares of MAXIMUS by 39.2% in the third quarter. Schwab Charles Investment Management Inc. now owns 689,814 shares of the health services provider’s stock worth $44,494,000 after buying an additional 194,225 shares during the last quarter. Finally, Mackenzie Financial Corp lifted its stake in shares of MAXIMUS by 18.7% in the third quarter. Mackenzie Financial Corp now owns 1,159,102 shares of the health services provider’s stock worth $74,762,000 after buying an additional 182,494 shares during the last quarter. Institutional investors and hedge funds own 95.67% of the company’s stock.
ILLEGAL ACTIVITY WARNING: This story was first published by The Lincolnian Online and is the property of of The Lincolnian Online. If you are accessing this story on another website, it was copied illegally and republished in violation of US & international copyright laws. The original version of this story can be read at https://www.thelincolnianonline.com/2018/03/14/maximus-inc-mms-given-consensus-recommendation-of-hold-by-analysts.html.
MAXIMUS Company Profile
MAXIMUS, Inc provides business process services (BPS) to government health and human services agencies. The Company operates through three segments: U.S. Federal Services, Health Services and Human Services. The U.S. Federal Services segment provides BPS and program management for large government programs, independent health review and appeals services for both the United States Federal Government, and state-based programs and technology solutions for civilian federal programs.
Receive News & Ratings for MAXIMUS Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MAXIMUS and related companies with MarketBeat.com's FREE daily email newsletter.